KR20240067919A - 비형질전환 대식세포 세포주의 생성 방법 - Google Patents

비형질전환 대식세포 세포주의 생성 방법 Download PDF

Info

Publication number
KR20240067919A
KR20240067919A KR1020247012001A KR20247012001A KR20240067919A KR 20240067919 A KR20240067919 A KR 20240067919A KR 1020247012001 A KR1020247012001 A KR 1020247012001A KR 20247012001 A KR20247012001 A KR 20247012001A KR 20240067919 A KR20240067919 A KR 20240067919A
Authority
KR
South Korea
Prior art keywords
macrophages
porcine
cells
csf
transformed
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020247012001A
Other languages
English (en)
Korean (ko)
Inventor
기오르기 페예르
저스티나 로파테카
Original Assignee
유니버시티 오브 플리머쓰
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB2113747.6A external-priority patent/GB202113747D0/en
Priority claimed from GBGB2210102.6A external-priority patent/GB202210102D0/en
Application filed by 유니버시티 오브 플리머쓰 filed Critical 유니버시티 오브 플리머쓰
Publication of KR20240067919A publication Critical patent/KR20240067919A/ko
Pending legal-status Critical Current

Links

Classifications

    • A61K39/4614—
    • A61K39/4622—
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/17—Monocytes; Macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0645—Macrophages, e.g. Kuepfer cells in the liver; Monocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/22—Colony stimulating factors (G-CSF, GM-CSF)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/13—Coculture with; Conditioned medium produced by connective tissue cells; generic mesenchyme cells, e.g. so-called "embryonic fibroblasts"
    • C12N2502/1323—Adult fibroblasts
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/13—Coculture with; Conditioned medium produced by connective tissue cells; generic mesenchyme cells, e.g. so-called "embryonic fibroblasts"
    • C12N2502/1352—Mesenchymal stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/11—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from blood or immune system cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/13—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells
    • C12N2506/1346—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells from mesenchymal stem cells
    • C12N2506/1353—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells from mesenchymal stem cells from bone marrow mesenchymal stem cells (BM-MSC)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/04—Immortalised cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
KR1020247012001A 2021-09-27 2022-09-22 비형질전환 대식세포 세포주의 생성 방법 Pending KR20240067919A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB2113747.6A GB202113747D0 (en) 2021-09-27 2021-09-27 Method for the generation of non-transformed macrophage cell line
GB2113747.6 2021-09-27
GBGB2210102.6A GB202210102D0 (en) 2022-07-09 2022-07-09 Method for generation of non-transformed macrophage cell line
GB2210102.6 2022-07-09
PCT/EP2022/076456 WO2023046873A1 (en) 2021-09-27 2022-09-22 Method for the generation of non-transformed macrophage cell line

Publications (1)

Publication Number Publication Date
KR20240067919A true KR20240067919A (ko) 2024-05-17

Family

ID=83995013

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020247012001A Pending KR20240067919A (ko) 2021-09-27 2022-09-22 비형질전환 대식세포 세포주의 생성 방법

Country Status (9)

Country Link
EP (1) EP4408983A1 (https=)
JP (1) JP2024534503A (https=)
KR (1) KR20240067919A (https=)
AR (1) AR127140A1 (https=)
AU (1) AU2022351386A1 (https=)
CA (1) CA3233040A1 (https=)
MX (1) MX2024003500A (https=)
UY (1) UY39959A (https=)
WO (1) WO2023046873A1 (https=)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014012933A1 (en) * 2012-07-16 2014-01-23 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Method for the generation of non-transformed macrophage cell lines

Also Published As

Publication number Publication date
EP4408983A1 (en) 2024-08-07
MX2024003500A (es) 2024-04-04
WO2023046873A1 (en) 2023-03-30
CA3233040A1 (en) 2023-03-30
UY39959A (es) 2023-04-14
AR127140A1 (es) 2023-12-20
AU2022351386A1 (en) 2024-04-04
JP2024534503A (ja) 2024-09-20

Similar Documents

Publication Publication Date Title
US8133732B2 (en) Method of forming myeloid precursor cells from human embryonic stem cells
CN110088272B (zh) 用于将细胞重编程为树突状细胞或抗原呈递细胞的组合物、其方法和用途
KR101946785B1 (ko) 영장류 다능성 줄기 세포의 조혈계 세포로의 분화
JP5954918B2 (ja) 未成熟な単球性樹状細胞の活性化を誘導するための組成物および方法
CN109722415A (zh) 一种造血干细胞的培养组合物、培养基以及造血干细胞的培养方法
PL209998B1 (pl) Sposób in vitro lub ex vivo różnicowania monocytarnych prekursorów komórek dendrytycznych w niedojrzale komórki dendrytyczne
JP2009518045A5 (https=)
Moro et al. Innate lymphoid cells, possible interaction with microbiota
Boudreau et al. Leukoreduction system chambers are a reliable cellular source for the manufacturing of T‐cell therapeutics
US20230015932A1 (en) Method of generation of lympho-myeloid niches
Van Breedam et al. Lack of strong innate immune reactivity renders macrophages alone unable to control productive Varicella-Zoster Virus infection in an isogenic human iPSC-derived neuronal co-culture model
Konduri et al. Modeling dendritic cell vaccination for influenza prophylaxis: potential applications for niche populations
Ibisch et al. Functional canine dendritic cells can be generated in vitro from peripheral blood mononuclear cells and contain a cytoplasmic ultrastructural marker
KR20240067919A (ko) 비형질전환 대식세포 세포주의 생성 방법
CN109536444A (zh) 一种适用于恶性实体瘤肿瘤浸润t淋巴细胞的分离诱导方法
US20240392246A1 (en) Method for the Generation of Non-Transformed Macrophage Cell Line
US9149515B2 (en) Interferon-alpha-producing bone marrow dendritic cells
Cody et al. Generation of dendritic cells from rabbit bone marrow mononuclear cell cultures supplemented with hGM-CSF and hIL-4
Bandi et al. Human embryonic stem cell (hES) derived dendritic cells are functionally normal and are susceptible to HIV-1 infection
CN118019841A (zh) 用于产生非转化巨噬细胞系的方法
JP2024518632A (ja) 体液免疫系の再生方法およびその使用
Kaur STUDIES ON IDENTIFICATION OF THE MOLECULAR TARGET OF INFECTIOUS BURSAL DISEASE VIRUS ON CHICKEN LYMPHOCYTES
Grau-Vorster et al. number of doses of CMV-specific cytotoxic T cells was successfully performed.

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000

E13 Pre-grant limitation requested

Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000